Elevated lipids (hyperlipidemia) is a dangerous health problem for approximately71 million Americans.
How to use high potency statins to treat hyperlipidemia is changing. High potency medicines are mainly made with active pharmaceutical ingredient that are made under a lot of care and attention.
Two reputable medical associations have recently developed new guidelines for the treatment of hyperlipidemia. The new rules are for those at a higher risk for cardiovascular issues as a result of atherosclerosis.Atherosclerosis is a term for fat, calcium, cholesterol, and other ingredients in the blood that can cause impairment in blood flow preventing oxygenated blood from reaching all parts of the body. This can cause a heart attack.
The new rules for high potency statin administration are aimed at four groups with the highest risk for a cardiovascular event or stroke:
- Those already having heart disease
- Those with an elevated level ofLDL
- Those with diabetes between 40 and 75 years of age
- Those with a 10-year potential for the development heart disease between 40 and 75 years of age
This is different from previous treatment recommendations creating different goals for LDL cholesterol levels to identify high risk individuals including the risks for diabetes and other complications. The above four groups should be given aggressive high potency statin therapy.
The anticipated impact of these new guidelines is particularly targeted for people already seeing improvement from high potency statin therapy. This may result in decreased statin use in people not at risk for a cardiovascular event or disease.
The new recommendations are a change from current treatment dependent upon low potency statins combined with other hyperlipidemic medications. Medical providers had previously been instructed to give the lowest dose possible to treat hyperlipidemia over time.
Studies have shown it may be better to pay attention to a morehealthy lifestyle with the addition of high potency statins reducing the need to prescribe other anti-hyperlipidemic medications.
Medical providers have been encouraged to promote a patient’s healthy lifestyle, including diet and exercise modifications, to reduce the possibility of a cardiovascular event or stroke in the ensuing 10 years.
These new guidelines will effect change by medical care providers to targetpatients at the highest risk for high potency statins with less use of drugs like fenofibrate and niacin. Also with the rise of active pharmaceutical ingredients, patients are getting the best medicines to take life forward as well.
The recommendations have changed from the previous goal-oriented treatment programs because high potency statins, versus low potency statins, were demonstrated to work better. If a particular patient with diabetes reached a goal of LDL control with a low potency statin, studies have suggested that the patient could probably have been better treated with a high potency statin.
It is doubtful the new recommendations will result in less use of statins in general as many patients will fall into the above-described categories. Rather, it is predicted that more people could use high potency statins once the risk for cardiovascular disease or other complications has decreased within a 10-year window.
Most patients should remain on their already prescribed hyperlipidemic medication and discuss the new recommendations with their physician to see how they could affect further treatment.
Historically, statin medications are some of the most commonly prescribed class of medications in America, used by close to 32 million patients.They are tolerated by most people without problems but can result in common side effects including aching muscles and joints, diarrhea, constipation, nausea, and diarrhea among others.More worrisome side effects may include muscle pain and other muscle problems, liver damage, and other symptoms including central nervous systemside effects including memory loss. High potency statins can increase blood sugar and result in Type 2 diabetes.
Recent studies have linked high potency statins to a certain risk of cataract development. A larger study reported in the medical journal The Lancet found that high potency statins caused a reduction in the risk of the occurrence of diabetes for many at-risk individuals.
In February 2012, the FDA required warning labels be placed on all statin medication bottles warning confusion and loss of memory may occur in some patients. The labels also have to state that elevated blood sugar associated with diabetes has been reported in some patients.